[HTML][HTML] COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials

…, PM Kasi, B Solomon, HH Loong, H Park… - Nature reviews Clinical …, 2021 - nature.com
Emerging efficacy data have led to the emergency use authorization or approval of COVID-19
vaccines in several countries worldwide. Most trials of COVID-19 vaccines excluded …

Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children

…, S Lanzkron, MC Beach, C Haywood, H Park… - …, 2008 - publications.aap.org
CONTEXT. Hydroxyurea is the only approved medication for the treatment of sickle cell
disease in adults; there are no approved drugs for children. OBJECTIVE. Our goal was to …

A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease

…, S Lanzkron, JJ Strouse, R Wilson, H Park… - Journal of the National …, 2009 - Elsevier
Clinical experts have expressed concern about underutilization of sickle cell disease (SCD)
therapies, including hydroxyurea, prophylactic antibiotics, iron chelation, bone marrow …

Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology

…, M McNamara, MF Mulcahy, D Outlaw, H Park… - Journal of the National …, 2022 - jnccn.org
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of
gastric cancers are adenocarcinomas, which are typically classified based on anatomic …

Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology

…, M McNamara, MF Mulcahy, RK Paluri, H Park… - Journal of the National …, 2019 - jnccn.org
Esophageal cancer is the sixth leading cause of cancer-related deaths worldwide.
Squamous cell carcinoma is the most common histology in Eastern Europe and Asia, and …

[HTML][HTML] Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study

S Modi, H Park, RK Murthy, H Iwata… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …

Targeting HER2 with trastuzumab deruxtecan: a dose-expansion, phase I study in multiple advanced solid tumors

…, H Iwata, I Krop, PA Jänne, T Doi, S Takahashi, H Park… - Cancer discovery, 2020 - AACR
T-DXd demonstrated promising activity in a heterogeneous patient population with heavily
pretreated HER2-expressing or HER2 -mutant solid tumors, especially HER2 -mutant NSCLC…

Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous …

…, NV Uboha, KL Stephans, JM Johnson, H Park… - The Lancet …, 2022 - thelancet.com
Background Patients with non-small-cell lung cancer (NSCLC) that is resistant to PD-1 and
PD-L1 (PD[L]-1)-targeted therapy have poor outcomes. Studies suggest that radiotherapy …

Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial

…, KM Moore, MR Patel, J Chaves, H Park… - JAMA …, 2019 - jamanetwork.com
Importance Current treatment options for progressive ovarian cancer provide limited benefit,
particularly in patients whose disease has become resistant to platinum-based …

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion …

…, IE Krop, C Redfern, Y Sagara, T Doi, H Park… - The Lancet …, 2019 - thelancet.com
Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent …